Search documents
Q1预告略超预期,资源公共事业及出口高增
ZHONGTAI SECURITIES· 2024-04-08 16:00
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% within the next 6 to 12 months [8][15]. Core Insights - The company, Huace Navigation, is a leader in high-precision navigation and positioning, providing hardware and various scene solutions while developing core algorithms and gradually expanding into SaaS subscription services, which are expected to enhance profitability [5][11]. - The company has reported strong growth in Q1, with a forecasted net profit of 1.03 billion to 1.06 billion yuan, representing a year-on-year increase of 26.48% to 34.06% [10][11]. - The company is actively expanding its industry applications and enhancing brand influence, with significant revenue growth in sectors such as resources and public utilities, as well as overseas markets [3][11]. Financial Performance Summary - **Revenue Forecast**: The company’s revenue is projected to grow from 2,236 million yuan in 2022 to 4,574 million yuan by 2025, with a compound annual growth rate (CAGR) of approximately 33% [1]. - **Net Profit Forecast**: Net profit is expected to increase from 361 million yuan in 2022 to 763 million yuan in 2025, reflecting a CAGR of about 32% [1]. - **Earnings Per Share (EPS)**: EPS is forecasted to rise from 0.66 yuan in 2022 to 1.40 yuan in 2025 [1]. - **Valuation Metrics**: The Price-to-Earnings (P/E) ratio is projected to decrease from 40.3 in 2022 to 19.1 in 2025, indicating improving valuation as earnings grow [1]. Market Position and Strategy - The company is focusing on enhancing its research and development capabilities, with R&D expenses amounting to 3.07 billion yuan in the first three quarters of 2023, which is 16.84% of its revenue [19]. - Huace Navigation is expanding its global market presence and product offerings, particularly in high-precision positioning technologies, benefiting from the integration of technologies like BeiDou, 5G, and cloud computing [11][19]. - The company has established multiple R&D bases in China and the UK, leveraging local talent to strengthen its technological capabilities [19].
量价齐升推升业绩,黄金龙头加速向经济优势转化

ZHONGTAI SECURITIES· 2024-04-08 16:00
量价齐升推升业绩,黄金龙头加速向经济优势转化 山东黄金(600547.SH)/有色金属 证券研究报告/公司点评 2024年04月09日 [Table_Industry] [评Ta级ble:_T买itle入] (维持) [公Ta司ble盈_F利in预anc测e]及 估值 市场价格:31.78元 指标 2022A 2023A 2024E 2025E 2026E 营业收入(百万元) 50,306 59,275 75,781 82,633 89,132 分析师:郭中伟 增长率yoy% 48% 18% 28% 9% 8% 执业证书编号:S0740521110004 归母净利润(百万元) 1,246 2,328 4,588 5,648 6,675 Email:guozw@zts.com.cn 增长率yoy% 743% 87% 97% 23% 18% 每股收益(元) 0.28 0.52 1.03 1.26 1.49 每股现金流量 0.66 1.53 2.95 3.95 4.42 分析师:谢鸿鹤 净资产收益率 3% 4% 8% 9% 9% 执业证书编号:S0740517080003 P/E 114.1 61.1 31.0 2 ...
福莱特事件点评:窑炉陆续投产+价格预期上涨,24年量价弹性可期

ZHONGTAI SECURITIES· 2024-04-08 16:00
JKLMNI!#OPQRFS+/TAUVWX24YZ/[\]U JKL(601865.SH)/^_‘ bcde;I! 2024Y4f8g a [Table_Industry] [!Ta"ble#_T$itle%] &’() [=Ta>ble?_F@inAancBe1C] DE !"#$%29.27& 23 2022A 2023A 2024E 2025E 2026E m-nop78&q 15,461 21,524 25,822 33,628 40,674 ’()%*+ rstyoy% 77% 39% 20% 30% 21% ,-./01%S0740522020001 uvwp78&q 2,123 2,760 3,852 5,179 6,394 Email%zengbiao@zts.com.cn rstyoy% 0% 30% 40% 34% 23% x5nyp&q 0.90 1.17 1.64 2.20 2.72 x5Yz9{ 0.08 0.84 2.10 2.28 2.77 ’()%23 u|}nyt 15% 12% 15% 17% 17% ,-./01%S0740522040004 P/E 32.4 24.9 ...
中间体/原料药表现突出,GLP-1管线丰富
ZHONGTAI SECURITIES· 2024-04-08 16:00
Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a total revenue of 137.40 billion CNY in 2023, representing a year-on-year growth of 21.22%, while the net profit reached 27.01 billion CNY, up 70.85% year-on-year [4][7] - The intermediate and raw material drug segments showed strong performance, with revenue from intermediates and raw materials growing by 44.9% and 23.7% respectively [4][7] - The company has a rich pipeline in the diabetes field, with significant progress in GLP-1 products, including the submission of liraglutide injection for production and completion of Phase III clinical enrollment for semaglutide injection [12][14] Financial Performance - The company's revenue forecast for 2024-2026 is projected at 150.47 billion CNY, 158.06 billion CNY, and 165.92 billion CNY, with respective year-on-year growth rates of 9.40%, 5.04%, and 4.97% [4][17] - The net profit forecast for the same period is expected to be 28.70 billion CNY, 29.95 billion CNY, and 31.15 billion CNY, with year-on-year growth rates of 6.23%, 4.36%, and 4.00% [4][17] - The gross margin for 2023 was 46.11%, an increase of 2.27 percentage points, while the net margin was 19.66%, up 5.71 percentage points [9][10] Segment Performance - The formulation segment generated revenue of 50.24 billion CNY, with a growth of 10.2%, while the insulin series saw a decline of 4.93% to 11.18 billion CNY [4][7] - The antibiotic segment, including animal health products, achieved sales of 35.33 billion CNY, marking a growth of 15.3% [4][7] - The overseas business contributed 26.16 billion CNY in revenue, reflecting a growth of 10.3%, while domestic revenue reached 61.00 billion CNY, up 38.57% [4][7] Research and Development - The company has established a comprehensive coverage in the diabetes sector, with projects including degludec insulin injection and liraglutide injection [12][14] - Significant advancements in GLP-1 products were noted, with multiple clinical trials progressing and approvals being sought for various indications [12][14]
国防军工行业周报:持续推荐低空及卫星互联网投资机会,关注一季报有望超预期标的
ZHONGTAI SECURITIES· 2024-04-08 16:00
持续推荐低空及卫星互联网投资机会,关注一季报有望超预期标的 证券研究报告/行业周报 行业名称:国防军工 2024年4月8日 评级:增持(维持) [重Ta点ble公_F司in基anc本e]状 况 分析师: 陈鼎如 简称 股价 EPS PE PEG 评级 执业证书编号:S0740521080001 (元) 2021 2022 2023E 2024E 2021 2022 2023E 2024E 2023E 中航重机* 14.83 0.85 0.82 0.90 1.08 17.51 18.17 16.54 13.68 1.57 买入 Email:chendr01@zts.com.cn 中核科技 16.19 0.31 0.45 0.66 0.92 52.10 36.30 24.60 17.53 0.52 买入 中航沈飞* 35.72 0.86 1.18 1.09 1.25 41.30 30.38 32.73 28.48 1.07 买入 分析师: 马梦泽 航发动力* 33.23 0.45 0.57 0.53 0.85 74.58 58.08 62.32 38.87 -9.17 买入 航发控制* 17.86 0.37 0. ...
中泰证券【中泰研究丨晨会聚焦】银行戴志锋:30家上市银行综述│2023年业绩快报:营收压力分化与收敛,资产质量稳健
ZHONGTAI SECURITIES· 2024-04-08 16:00
【中泰研究丨晨会聚焦】银行戴志锋:30 家上市银行综述│2023 年业绩快报:营 收压力分化与收敛,资产质量稳健 证券研究报告 2024 年 4 月 08 日 [Table_Industry] [T[分Taa析bbll师ee__:TMi戴tlea志]in锋] 执业证书编号:S0740517030004 电话: [b_Suy 今日预览 Email: 今日重点 >> 【银行】戴志锋:30 家上市银行综述│2023 年业绩快报:营收压力分化 与收敛,资产质量稳健 研究分享 >> 【交运】杜冲:航空机场 4 月投资策略:出游正当时,逢低早布局 欢迎关注中泰研究所订阅号 晨报内容回顾: 请务必阅读正文之后的重要声明部分 晨会聚焦 今日重点 ►【银行】戴志锋:30 家上市银行综述│2023 年业绩快报:营收压力分化与收敛,资产质量稳健 戴志锋|中泰银行业首席 S0740517030004 盈利情况拆解:全年收入同比-3.8%、净利润同比+1.1%。1、营收同比-3.8%;边际略有企稳。主要 是 22 年 4 季度其他非息收入低基数效应的贡献。4 季度利息收入和手续费收入增速均边际下行, 其他非息收入在低基数的贡献下增速有 ...
中国中免23年年报点评:23年业绩符合预期,需求承压下估值或不低


ZHONGTAI SECURITIES· 2024-04-08 16:00
[Table_Industry] 23 年业绩符合预期,需求承压下估值或不低 ---中国中免23 年年报点评 中国中免(601888.SH)/休闲 证券研究报告/公司点评 2024年04月 09日 服务 [Table_Industry] [评Ta级ble:_I买nve入st(]维 持) [公Ta司ble盈_F利in预anc测e1及] 估值 市场价格:81.87元 指标 2022 2023 2024E 2025E 2026E 营业收入(百万元) 54,433 67,540 70,660 83,332 91,252 [分Ta析b师le:_A 张ut骥ho rs] 增长率yoy% -20% 24% 5% 18% 10% 执业证书编号:S0740523060001 归母净利润(百万元) 5,030 6,714 7,333 8,822 9,603 增长率yoy% -48% 33% 9% 20% 9% Email:zhangji01@zts.com.cn 每股收益(元) 2.43 3.25 3.54 4.26 4.64 [基Tab本le_P状rofit]况 每股现金流量 -1.65 7.31 3.23 6.31 5.85 ...
生物性资产价值变动影响利润,静待2024逐步恢复
ZHONGTAI SECURITIES· 2024-04-07 16:00
昭衍新药(603127.SH)/医药生物 证券研究报告/公司点评 2024 年 04 月 07 日 | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
电力设备与新能源行业周报:预计锂电通缩结束,江苏国信850MW海风启动风机采购
ZHONGTAI SECURITIES· 2024-04-07 16:00
2 !"#$%&’()*+,-850MW./01/234 $56789:; <=>?@A/BCD@ 2024E4F7G HIJKLM NL O [ \Ta ]ble ^_F _in Panc Qe] R S !"#$%& CI EPS PE JK GH PEG ’()*+,$S0740522020001 (=) 2022A 2023E 2024E 2025E 2022 2023E 2024E 2025E Email$zengbiao@zts.com.cn !"#$ 23.89 2.97 0.98 0.80 1.09 8.05 24.31 29.93 21.92 -0.3 %& ’()* 42.10 4.46 3.80 3.41 4.02 9.44 11.08 12.34 10.46 2.4 %& !+,- 24.05 1.69 2.55 3.52 4.39 14.20 9.43 6.83 5.48 0.1 - !"#$-. .,/0 104.88 2.42 4.70 6.40 8.16 43.35 22.31 16.39 12.85 0.2 %& ’()*+,$S0740522040004 123 112.2 ...
有色金属行业周报:3月智利锂盐出口环比持稳,锂价维持震荡
ZHONGTAI SECURITIES· 2024-04-07 16:00
[Table_Industry] 证券研究报告/行业周报 2024年4月7日 有色金属 3月智利锂盐出口环比持稳,锂价维持震荡 [T[评aTab 级blele_ :_MT增aitilne持]] (维持) [投Ta资bl要e_点Su mmary] 1. 【关键词】24年3月智利对中国出口锂盐16095吨,环比增加0.2%, 分析师:安永超 同比增加 19.8%;北方稀土发布 4 月挂牌价,氧化镨钕报价 36.57 万 执业证书编号:S0740522090002 元/吨,环比持平 Email:anyc@zts.com.cn 2. 投资策略:维持行业“增持”评级,中长线继续推荐稀土永磁、锑和 分析师:郭中伟 锡板块: 执业证书编号:S0740521110004 ➢ 1)稀土:短期需求低迷导致价格疲软,中长期机器人、新能源汽 ➢ 车、工业节能电机等多个消费场景有望爆发。国务院《推动大规 Email:guozw@zts.com.cn 模设备更新和消费品以旧换新行动方案》提出,到2027年重点行 分析师:谢鸿鹤 业主要用能设备能效基本达到节能水平,假设2025年新增高效节 执业证书编号:S0740517080003 能电 ...